Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
HETEROCYCLIC COMPOUND SERVING AS FGFR4 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2017/202390
Kind Code:
A1
Abstract:
Provided in the present invention is a heterocyclic compound serving as an FGFR4 (fibroblast growth factor receptor 4) inhibitor. Specifically, provided in the present invention is the compound shown in formula (I), including isomers (enantiomers or diastereoisomers) that may exist, or a pharmaceutically acceptable salt, a prodrug, a deuterated derivative, a hydrate, or a solvate thereof. The definition of each group in formula (I) is set forth in the description. The compound of the present invention has FGFR4 inhibitory activity and may be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and may also be used in combination with other drugs for the treatment of various related diseases.

Inventors:
ZHANG HANCHENG (CN)
LIU SHIFENG (CN)
YE XIANGYANG (CN)
Application Number:
PCT/CN2017/086445
Publication Date:
November 30, 2017
Filing Date:
May 27, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HANGZHOU INNOGATE PHARMA CO LTD (CN)
International Classes:
C07D471/04; A61K31/4375; A61K31/496; A61K31/506; A61K31/5383; A61P35/00; C07D498/04; C07D519/00
Domestic Patent References:
WO2015059668A12015-04-30
Other References:
See also references of EP 3483158A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: